Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22715892 | 0.91 | FFAR1 (0.56) | FFAR1DGAT1PDK2L3MBTL1 | |
| SCHEMBL22657321 | 0.81 | FFAR1 (0.51) | FFAR1DGAT1L3MBTL1 | |
| SCHEMBL25248244 | 0.80 | FFAR1 (0.53) | FFAR1PDK2L3MBTL1 | |
| SCHEMBL29236822 | 0.79 | FFAR1 (0.54) | FFAR1PDK2L3MBTL1 | |
| SCHEMBL17785673 | 0.79 | FFAR1 (0.54) | FFAR1DGAT1PDK2L3MBTL1 | |
| SCHEMBL27091002 | 0.77 | FFAR1 (0.50) | FFAR1DGAT1L3MBTL1 | |
| SCHEMBL1561022 | 0.77 | FFAR1 (0.50) | FFAR1DGAT1L3MBTL1 | |
| SCHEMBL25297920 | 0.77 | FFAR1 (0.58) | FFAR1DGAT1PDK2 | |
| SCHEMBL25293264 | 0.77 | FFAR1 (0.58) | FFAR1DGAT1PDK2 | |
| SCHEMBL25248137 | 0.77 | FFAR1 (0.53) | FFAR1DGAT1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | FFAR1 2345/4885DGAT1 3924/4885PDK2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.